Keys to successful clinical translation of next-gen oncolytic virotherapies

Jochen Stritzker is a microbiologist by training and has received his PhD at the University of Würzburg where he also received his venia legendi. With more than 16 years in immuno-oncology, he has gained experience in transitioning product candidates from discovery research to advanced clinical trials. He joined Themis as Senior Vice President Immunotherapy in January 2019 where he started leading the then newly established immuno-oncology program. In his prior roles he led discovery, preclinical, as well as clinical trial-supporting translational research using oncolytic viruses and various therapeutic approaches that take advantage of combination strategies.

Please enter your email to access content Read now